- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04793711
EpiCeram for Skin Protection in Healthcare Workers Using Personal Protective Equipment
This is an open-label study using a study device currently being prescribed by doctors. This means everyone involved in the study will know the name of the product, only one product will be used, and the U.S. Food and Drug Administration (FDA) has approved the sale of this product. Although this is called a device, the product is an emollient-type lotion.
Healthcare workers (HCW) often suffer from signs and symptoms of skin irritation, including pain, redness, roughness, dryness, cracking and itching due to the extensive use of personal protective equipment (PPE) such as masks and gloves. These are thought to be due to changes in the normal skin barrier function induced by repeated minor abrasion in the warm, moist environment induced by extensive use of PPE required at work. EpiCeram® Controlled Skin Barrier Emulsion (EpiCeram) is a prescription skin barrier repair product containing ingredients specifically designed to improve skin barrier function in people with diseases known to be associated with barrier defects such as atopic and contact dermatitis. However, EpiCeram has not previously been studied in people with skin irritation due to extensive use of PPE.
Study Overview
Detailed Description
Description of Procedures At the screening visit, the study will be explained, and the subject will have the opportunity to ask questions. If the subject decides to participate, the subject will have to read, sign and date this Informed Consent Document. The study staff will take the subjects pertinent medical history to evaluate the subjects eligibility for the study. The subject will be asked about the kind of skin products the subject is using as well as about the subjects use of PPE. The subject will rate the subject overall skin irritation on a scale of 0 to 10 with 10 (ten) being worst and 0 (zero) being none. The subject will have to score at least 4 (four) on the overall skin irritation scale to continue in the study.
If the subject had not used any lotions or emollients for the previous one (1) week on the face and hands, Visit 2 activities may be performed at the Screening visit. If the subject had used any lotions or emollients on the face and hands, a washout period will be necessary, and the subject will be asked to refrain from using any lotions and emollients for one (1) week between Visits 1 and 2 and then, for the duration of the study. Visit 2 (Baseline) will occur seven (7) days after Visit 1.
If the subject is accepted into the study, the subject will return to the study site one (1) week later and 28-days later, at which times the subject will complete the same overall irritation scale. The subject will have measurements of skin barrier function tested, specimens of surface cells collected and special photographs taken, all described below.
Photographs: Special 3-D photographs will be taken by a digital camera that records the skin microstructure and wrinkles. This 3D photo will be analyzed and used to assign a number to measure skin roughness and wrinkles and track changes over time. These are not conventional photographs, and the subject cannot be identified. Additional privacy steps will include assigning a number to all documents instead of the subject name.
Skin Function Testing: Measurements of skin water loss and surface skin pH, also known as acidity, will be taken on the skin between the subject knuckles. These measurements are performed by a short, rod-type device, emitting light, placed lightly onto the subject skin. There is no sensation felt and the result is available within seconds.
Laboratory Testing: Two types of specimens will be obtained: a swab and tape stripping. A single skin swab (similar to cotton Q-tips®) will be wiped across the subject palm to collect bacteria. Non-invasive tape stripping of surface cells will be performed at 2 places on the back of the subject hand. This is done by laying a specially made piece of tape, gently on the subject skin and removing it, 3 times, to lift the surface cells. The specimens will be used to estimate the presence, type, and number of specific bacteria.
Finally, the subject will be asked to avoid applying any skin products (except make-up) to the subject skin for the following week and for the duration of the study.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Arizona
-
Peoria, Arizona, United States, 85381
- Sun Valley Arthritis Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- HCW using PPE at least 6 hours/day, 4 days/week or, depending on shift work, 24 hours/week, for at least one (1) month
- Men or women, any age
- Overall skin irritation score of at least 4 on 0-10 scale where 0 = none and 10 = worst
- Willing to stop use of any other emollient and lotion for one (1) week between screening and baseline visit and for the duration of the study.
- Participant is willing to stop use of or not begin use of any topical corticosteroids, emollients and lotions to the hands and face for the duration of the trial.
Exclusion Criteria:
- History of any skin disorder existing prior to March 1, 2020 characterized by chronic visible lesions or skin irritation symptoms including, but not limited to atopic dermatitis, eczema, moderate-severe acne, chronic dry skin and psoriasis.
- Use of topical corticosteroids within one (1) month of baseline visit.
- History of any significant medical condition that, in the opinion of the investigator, might put the subject at risk in this trial.
- Participation in another clinical trial within 30 days or 5 half-lives of the study agent, whichever is longer.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: EpiCeram
Open-Label, 3 (three) times per day, topical, to hands and face, for 28 days.
|
Barrier cream
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
a. Change in Patient Reported Outcome of Overall Face and Hand Skin Irritation Symptoms From Baseline to Day 28, of at Least 2 Points on a 0-10 Point Scale Where 0 = None and 10 = Worst.
Time Frame: From baseline to Day 28
|
A subjective assessment by the subject of combined, overall irritation of face and hands using an ordinal scale of 0-10 where 0 = no irritation and 10 = worst irritation felt
|
From baseline to Day 28
|
b. Change in Any Two Specific Skin Irritation Symptoms of at Least 2 Points on a 0-10 Point Scale Where 0 = None and 10 = Worst.
Time Frame: From baseline to Day 28
|
A subjective assessment of irritation of face and hands for each of 7 symptoms using an ordinal scale of 0-10 where 0 = no irritation and 10 = worst irritation felt
|
From baseline to Day 28
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Robert Levy, MD, Director of Clinical development
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PPE-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Irritant Contact Dermatitis
-
University of Split, School of MedicineRecruitingContact DermatitisCroatia
-
University of Split, School of MedicineRecruitingContact Dermatitis | Contact Dermatitis IrritantCroatia
-
University of Split, School of MedicineCompletedIrritant Contact DermatitisCroatia
-
Steven BakerCompletedContact Dermatitis of HandUnited States
-
HealthPartners InstituteCompletedIrritant Contact DermatitisUnited States
-
Hospices Civils de LyonRecruitingContact Dermatitis | Contact Dermatitis Irritant | Contact Dermatitis, AllergicFrance
-
University Ghent3MTerminatedPressure Ulcer | Diaper Rash | Incontinence-associated Dermatitis | Irritant Contact Dermatitis Due to IncontinenceBelgium
-
Copenhagen University Hospital at HerlevTerminatedType 1 Diabetes | Contact Dermatitis IrritantDenmark
-
University GhentUniversity Hospital, GhentCompletedPressure Ulcer | Diaper Rash | Incontinence-associated Dermatitis | Irritant Contact DermatitisBelgium
-
University Ghent3MCompletedDiaper Rash | Incontinence-associated Dermatitis | Irritant Contact DermatitisBelgium
Clinical Trials on EpiCeram
-
University of MelbourneActive, not recruitingAsthma | Eczema | Allergy;FoodAustralia
-
Indiana UniversityNational Institute of Nursing Research (NINR)RecruitingDiabetic Foot Ulcers | Burn Wound | Wound | Chronic Wound | Pressure Ulcers | Venous Leg Ulcers | ChronicUnited States
-
Johnson & Johnson Consumer Products Company Division...CompletedAtopic DermatitisUnited States
-
Johnson & Johnson Consumer and Personal Products...Completed
-
Promius Pharma, LLCCompletedAtopic DermatitisUnited States
-
Johnson & Johnson Consumer Inc. (J&JCI)Terminated
-
Stanford UniversityEnd Allergies Together (EAT)Completed
-
Wake Forest University Health SciencesCompletedAtopic DermatitisUnited States
-
Johnson & Johnson Consumer Inc. (J&JCI)CompletedAtopic DermatitisUnited States
-
Ceragenix PharmaceuticalsCompleted